Antihypertensive Duration of Action of Cilazapril in Patients with Mild to Moderate Essential Hypertension

Drugs

Volumn 41, Issue 1, 1991, Pages 31-36

  Kobrin, I ^a,b   Guntzel P ^b   Viskoper, R ^c   Paran, E ^d   Zimlichman, R ^d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c BARZILAI MEDICAL CENTER   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CILAZAPRIL; PLACEBO;

ADULT; AGED; BLOOD PRESSURE; CONFERENCE PAPER; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CILAZAPRIL; COMPARATIVE STUDY; DIASTOLE; DOUBLE-BLIND METHOD; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGE; POSTURE; PYRIDAZINES; TIME FACTORS;

EID: 0026081043     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199100411-00007     Document Type: Article

References (8)

1. Effective dose range of enalapril in mild to moderate essential hypertension
2. How study design affects outcomes in comparisons of therapy. I. Medical
3. Enalapril-induced cough
4. Cilazapril: a new non-thiol-containing angiotensin-converting enzyme inhibitor
5. Some problems with antihypertensive drug studies in the context of the new guidelines
6. Chronic dose-response curve of enalapril in essential hypertension
7. Study designs for dose ranging